Cambrex Buys Immortalized Cell Line Assets from XCellsyz
Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech XCellsyz, Cambrex said last week.
Financial terms of the deal were not disclosed.
Two weeks ago, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron’s human telomerase reverse transcriptase technology (see Inside Bioassays, 1/18/2005). XCellsyz last year had signed a similar agreement for Geron’s telomerase technology, which it used to develop its own immortalized cell lines.
Cambrex said it will use the recently acquired XCellsyz technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.
Sigma-Aldrich to Buy JRH Biosciences for $370M
Sigma-Aldrich will acquire JRH Biosciences, a division of CSL Limited, for $370 million in cash, the company said last week.
JRH, headquartered in Lenexa, Kan., supplies cell culture and sera products to the biopharmaceutical industry. It had approximately $150 million in sales in 2004, and was expecting a 10-percent growth in this figure in 2005, Sigma said.
JRH also has manufacturing facilities in the US, Europe, and Australia; and serum collection and processing centers in the US and Australia. It has approximately 400 employees worldwide.
Sigma said that it expects to fund the acquisition with a combination of existing cash, short-term debt, and three-year term debt.
Goldman Sachs acted as financial advisor on the transaction.